


CB2 receptor agonist 2

| | | | |
|--------------------|---|-------|----------|
| Cat. No.: | HY-132217 | | |
| CAS No.: | 1314230-75-5 | | |
| Molecular Formula: | C ₃₀ H ₃₆ N ₂ O ₄ | | |
| Molecular Weight: | 488.62 | | |
| Target: | Cannabinoid Receptor | | |
| Pathway: | GPCR/G Protein; Neuronal Signaling | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

Ethanol : 30 mg/mL (61.40 mM; Need ultrasonic and warming)

| | Solvent Concentration | Mass | 1 mg | 5 mg | 10 mg |
|------------------------------|--------------------------|------|-----------|------------|------------|
| | | | | | |
| Preparing Stock Solutions | 1 mM | | 2.0466 mL | 10.2329 mL | 20.4658 mL |
| | 5 mM | | 0.4093 mL | 2.0466 mL | 4.0932 mL |
| | 10 mM | | 0.2047 mL | 1.0233 mL | 2.0466 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CB2 receptor agonist 2 is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor with a K_i of 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2^[1].

IC₅₀ & Target

CB2
8.5 nM (K_i)

In Vitro

CB2 receptor agonist 2 (compound 4g) (1 μM; 72 hours) has very low or no cytotoxicity to Hep-G2 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

| | |
|------------------|-------------------------------------|
| Cell Line: | Hep-G2 (Human hepatoblastoma) cells |
| Concentration: | 1 μM |
| Incubation Time: | 72 hours |

| | | | | | | | | | |
|-----------------|--|---------------|---|---------|--|-----------------|---|---------|--|
| | <table> <tr> <td>Result:</td><td>Exhibited very low or no cytotoxicity to Hep-G2 cells.</td></tr> </table> | Result: | Exhibited very low or no cytotoxicity to Hep-G2 cells. | | | | | | |
| Result: | Exhibited very low or no cytotoxicity to Hep-G2 cells. | | | | | | | | |
| In Vivo | <p>CB2 receptor agonist 2 (compound 4g) (1 and 3 mg/kg; 1 hour) is very potent (with maximal effect being reached already at the 1 mg/kg dose) and has antihyperalgesic effects, efficacious also on the first phase of the nocifensive response and strongly reduced by AM630 (CB2-selective antagonist/inverse agonist) ^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table> <tr> <td>Animal Model:</td><td>Formalin injection induces a biphasic stereotypical nocifensive behavior in mice^[1]</td></tr> <tr> <td>Dosage:</td><td>Formalin (1.25% in saline, 30 µL), 1 and 3 mg/kg CB2 receptor agonist 2, 1 mg/kg AM630, monitor every 5 minutes for 1 hour</td></tr> <tr> <td>Administration:</td><td>Injection in the dorsal surface of one side of the hindpaw (Formalin), i.p. (CB2 receptor agonist, AM630)</td></tr> <tr> <td>Result:</td><td>Elicited antihyperalgesic effects and potent (with maximal effect being reached already at the 1 mg/kg dose) and efficacious, strongly reduced by AM630.</td></tr> </table> | Animal Model: | Formalin injection induces a biphasic stereotypical nocifensive behavior in mice ^[1] | Dosage: | Formalin (1.25% in saline, 30 µL), 1 and 3 mg/kg CB2 receptor agonist 2, 1 mg/kg AM630, monitor every 5 minutes for 1 hour | Administration: | Injection in the dorsal surface of one side of the hindpaw (Formalin), i.p. (CB2 receptor agonist, AM630) | Result: | Elicited antihyperalgesic effects and potent (with maximal effect being reached already at the 1 mg/kg dose) and efficacious, strongly reduced by AM630. |
| Animal Model: | Formalin injection induces a biphasic stereotypical nocifensive behavior in mice ^[1] | | | | | | | | |
| Dosage: | Formalin (1.25% in saline, 30 µL), 1 and 3 mg/kg CB2 receptor agonist 2, 1 mg/kg AM630, monitor every 5 minutes for 1 hour | | | | | | | | |
| Administration: | Injection in the dorsal surface of one side of the hindpaw (Formalin), i.p. (CB2 receptor agonist, AM630) | | | | | | | | |
| Result: | Elicited antihyperalgesic effects and potent (with maximal effect being reached already at the 1 mg/kg dose) and efficacious, strongly reduced by AM630. | | | | | | | | |

REFERENCES

[1]. Pasquini S, et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice. J Med Chem. 20

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA